

Eva Blondeaux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2187020/publications.pdf>

Version: 2024-02-01

25
papers

433
citations

759233

12
h-index

752698

20
g-index

26
all docs

26
docs citations

26
times ranked

526
citing authors

#	ARTICLE	IF	CITATIONS
1	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	1.6	70
2	Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study. <i>Breast</i> , 2018, 41, 51-56.	2.2	41
3	Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. <i>Human Reproduction</i> , 2022, 37, 954-968.	0.9	41
4	Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1258-1267.	1.6	33
5	PICC-PORT totally implantable vascular access device in breast cancer patients undergoing chemotherapy. <i>Journal of Vascular Access</i> , 2020, 21, 460-466.	0.9	33
6	The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients. <i>BMC Cancer</i> , 2017, 17, 346.	2.6	30
7	T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. <i>Clinical Breast Cancer</i> , 2020, 20, e181-e187.	2.4	30
8	The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 690320.	2.8	23
9	Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review. <i>Clinical Medicine Insights Reproductive Health</i> , 2019, 13, 117955811986458.	3.9	20
10	Management of young women with early breast cancer. <i>ESMO Open</i> , 2018, 3, e000458.	4.5	15
11	Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 400-408.	6.3	15
12	Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. <i>British Journal of Cancer</i> , 2020, 122, 1611-1617.	6.4	12
13	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. <i>ESMO Open</i> , 2021, 6, 100300.	4.5	9
14	Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1153-1161.	3.1	8
15	News on the medical treatment of young women with early-stage HER2-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1643-1655.	1.8	8
16	Treatment with aromatase inhibitors and markers of cardiovascular disease. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 261-267.	2.5	7
17	Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492093181.	1.3	7
18	Tumor-to-nipple Distance Should Not Preclude Nipple-sparing Mastectomy in Breast Cancer Patients. Personal Experience and Literature Review. <i>Anticancer Research</i> , 2020, 40, 3543-3550.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020, 136, 43-51.	2.8	6
20	Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study. <i>ESMO Open</i> , 2020, 5, e000719.	4.5	5
21	Role of dose-dense chemotherapy in high-risk early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 480-485.	2.4	4
22	The Marginsâ€™™ Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast Cancer. <i>In Vivo</i> , 2022, 36, 814-820.	1.3	4
23	Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment. <i>Annals of Palliative Medicine</i> , 2020, 9, 512-516.	1.2	3
24	Update on Pregnancy Following Breast Cancer Diagnosis and Treatment. <i>Cancer Journal (Sudbury,)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	2
25	Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. <i>Tumori</i> , 2022, , 030089162110675.	1.1	1